Clonidine Use in Refractory Hypertension

Guideline-Based Recommendations

The American Heart Association explicitly recommends avoiding clonidine in patients with heart failure with reduced ejection fraction (HFrEF) because moxonidine, a related centrally-acting agent, was associated with increased mortality in this population 1, 2, 3
Clonidine is classified as Class III Harm (should not be used) in patients with hypertension and HF with reduced ejection fraction 3
The American College of Cardiology recommends maximizing ACE inhibitors or ARBs, beta-blockers, thiazide or thiazide-like diuretics, aldosterone receptor antagonists, and dihydropyridine calcium channel blockers before considering clonidine 1, 3

ACE inhibitors or ARBs should be maximized as first-line treatment, with proven mortality benefit 1, 3
Beta-blockers, such as carvedilol, metoprolol succinate, or bisoprolol, should be used in HF patients 1, 3
Thiazide or thiazide-like diuretics, such as chlorthalidone, should be used for resistant hypertension 1, 3
Aldosterone receptor antagonists, such as spironolactone or eplerenone, are particularly effective in resistant hypertension 3
Dihydropyridine calcium channel blockers, such as amlodipine or felodipine, are safe in HF patients 1, 2, 3

Monitor for rebound hypertension risk when discontinuing clonidine, and taper gradually over 2-4 days while monitoring blood pressure closely 4
Avoid clonidine in patients with moderate to severe hyponatremia, as the risk outweighs the benefit 4
Clonidine should not be used in patients with heart failure with reduced ejection fraction, due to the Class III Harm recommendation 3
Poor medication adherence is a contraindication for clonidine use, due to the risk of rebound hypertension with missed doses 4

The American College of Cardiology recommends clonidine as last-line therapy due to significant CNS adverse effects, especially in older adults, after maximizing other antihypertensive agents 5, 6

The standard oral dosing of clonidine is 0.1-0.8 mg twice daily, and the transdermal patch dosing is 0.1-0.3 mg weekly, as per the guidelines from the American College of Cardiology 5